Literature DB >> 9869585

Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis.

D B Hoellman1, G Lin, M R Jacobs, P C Appelbaum.   

Abstract

Agar dilution was used to test the activities of HMR 3647, erythromycin A, azithromycin, clarithromycin, roxithromycin, clindamycin, and quinupristin-dalfopristin against 235 strains of Enterococcus faecalis. HMR 3647 was the most active compound (MICs at which 50 and 90% of the isolates are inhibited [MIC50 and MIC90, respectively] of 0.06 and 4.0 microg/ml, respectively). The MIC50 and MIC90 (with the MIC50 given first and the MIC90 given second; both in micrograms per milliliter) for other compounds were as follows: 4.0 and >32.0 for erythromycin A, 16.0 and >32.0 for azithromycin, 2.0 and >32 for clarithromycin, 32.0 and >32.0 for roxithromycin, 32.0 and >32.0 for clindamycin, and 8.0 and 16.0 for quinupristin-dalfopristin. All compounds were only bacteriostatic.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9869585      PMCID: PMC89040     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states.

Authors:  B E Murray; K V Singh; S M Markowitz; H A Lopardo; J E Patterson; M J Zervos; E Rubeglio; G M Eliopoulos; L B Rice; F W Goldstein
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

2.  High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci.

Authors:  T M Coque; R C Arduino; B E Murray
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

Review 3.  Genetics and mechanisms of glycopeptide resistance in enterococci.

Authors:  M Arthur; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Increasing problems in the therapy of enterococcal infections.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

6.  Antimicrobial activity of RU-66647, a new ketolide.

Authors:  R N Jones; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  1997 Jan-Feb       Impact factor: 2.803

7.  Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group.

Authors:  S Gordon; J M Swenson; B C Hill; N E Pigott; R R Facklam; R C Cooksey; C Thornsberry; W R Jarvis; F C Tenover
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

8.  Ampicillin-resistant enterococcal species in an acute-care hospital.

Authors:  S E Oster; V A Chirurgi; A A Goldberg; S Aiken; R E McCabe
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 9.  Vancomycin resistance in the enterococcus. Relevance in pediatrics.

Authors:  L B Rice; D M Shlaes
Journal:  Pediatr Clin North Am       Date:  1995-06       Impact factor: 3.278

10.  Vancomycin resistance gene vanC is specific to Enterococcus gallinarum.

Authors:  R Leclercq; S Dutka-Malen; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  2 in total

1.  In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer.

Authors:  F Alcaide; M A Benítez; J Carratalà; F Gudiol; J Liñares; R Martín
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.